Transportation policy for campus climate action planning: Process and policy implications

This article discusses the innovative methods used to complete the transportation components of Cal Poly’s Climate Action Plan (CAP). The campus\u27s CAP was completed by a BSCRP studio during the fall and winter quarters (2015-2016AY) in collaboration with Facilities Planning and Capital Projects. Professors William Riggs and Adrienne Greve (instructors for the studio along with Chris Clark) developed the methods discussed here, and C. Kai Lord-Farmer was the graduate assistant who assisted in completing the technical analysis

Redesigning a Street Corridor in San Clemente, CA: South El Camino Real Urban Design Concept Plan

The South El Camino Real Urban Design Concept Plan was developed by a first-year MCRP studio for the City of San Clemente, CA. The San Clemente community, the City planners and the City Council welcomed the students’ ideas for making the corridor appealing, economically attractive, and safer for pedestrians and bicyclists

Cal Poly Climate Action Plan

The Cal Poly Climate Action Plan (PolyCAP) is designed to achieve the California State University (CSU) Chancellor’s mandate to reduce greenhouse gas (GHG) emissions to 1990 levels by 2020 and 80% below 1990 levels by 2040 (CSU, 2014). California Polytechnic State University, San Luis Obispo (Cal Poly) Facility Management and Development (FM&D) and the City and Regional Planning (CRP) Senior Community Planning Laboratory developed the PolyCAP during the Fall 2015 and Winter 2016 quarters, with editing and refinement in subsequent quarters. The goal of the PolyCAP is to reduce Cal Poly’s GHG emissions and to adapt the Campus to a changing climate. The PolyCAP aims to exceed the CSU mandate and achieve Net Zero GHG emissions by 2050, in accordance with Cal Poly’s signing of the Second Nature Climate Commitment. Cal Poly is updating its Master Plan to 2035, examining University academics, buildings, housing, transportation, agriculture, and more. The PolyCAP is intended to aid the Draft Master Plan Update to achieve its goal to be responsive to climate change. Many strategies of the PolyCAP can also be implemented as mitigation measures in the Draft Master Plan Update Environmental Impact Report (EIR)

Thigh-length compression stockings and DVT after stroke

Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials of more than 3000 patients. We undertook a systematic review and meta-analysis to assess the effect of such treatment on survival in patients with this disease

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatment groups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment and were twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants and local study staff were not masked to the allocated treatment, but all others involved in the trial were masked to the outcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) were eligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was 65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomly allocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall, 561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days (rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median 10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days (rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, no significant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24). Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or other prespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restricted to patients in whom there is a clear antimicrobial indication. Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research